OBJECTIVE: To address the activation and replicative activity of HERV-K102 in vivo associated with HIV viremia. DESIGN AND METHODS: Initially serology was performed on HERV-K102 specific envelope peptides to determine if HERV-K102 may become activated with HIV viremia. Before developing a quantitative PCR (qPCR) assay, we first determined whether plasma associated particles contained DNA or RNA genomes in a pilot study which surprisingly revealed predominantly DNA genomes. A relative, ddCt qPCR ratio method was then devised to detect excess levels of HERV-K102 pol DNA templates over genomic levels which served as a surrogate marker to reliably index the level of particles found in plasma. RESULTS: Both the peptide serology and ddCt qPCR excess ratio methods suggested the activation of HERV-K102 in about 70-80% of HIV viremic cases whereas only 2-3% of normal healthy adults had marginally activated HERV-K102 (P < 0.0001). Moreover, by digestion with dUTPase we were able to confirm that the vast majority of excess DNA template in plasma related to cDNA production rather than representing genomic copies. CONCLUSIONS: Our work uniquely suggests the common activation of HERV-K102 with HIV viremia and may be first to directly demonstrate HERV-K102 cDNA production in vivo. The potential implications of the induction of HERV-K102 activation and replication for the prevention and control of HIV are discussed.
OBJECTIVE: To address the activation and replicative activity of HERV-K102 in vivo associated with HIV viremia. DESIGN AND METHODS: Initially serology was performed on HERV-K102 specific envelope peptides to determine if HERV-K102 may become activated with HIV viremia. Before developing a quantitative PCR (qPCR) assay, we first determined whether plasma associated particles contained DNA or RNA genomes in a pilot study which surprisingly revealed predominantly DNA genomes. A relative, ddCt qPCR ratio method was then devised to detect excess levels of HERV-K102 pol DNA templates over genomic levels which served as a surrogate marker to reliably index the level of particles found in plasma. RESULTS: Both the peptide serology and ddCt qPCR excess ratio methods suggested the activation of HERV-K102 in about 70-80% of HIV viremic cases whereas only 2-3% of normal healthy adults had marginally activated HERV-K102 (P < 0.0001). Moreover, by digestion with dUTPase we were able to confirm that the vast majority of excess DNA template in plasma related to cDNA production rather than representing genomic copies. CONCLUSIONS: Our work uniquely suggests the common activation of HERV-K102 with HIV viremia and may be first to directly demonstrate HERV-K102 cDNA production in vivo. The potential implications of the induction of HERV-K102 activation and replication for the prevention and control of HIV are discussed.
Authors: Marta J Gonzalez-Hernandez; Michael D Swanson; Rafael Contreras-Galindo; Sarah Cookinham; Steven R King; Richard J Noel; Mark H Kaplan; David M Markovitz Journal: J Virol Date: 2012-05-16 Impact factor: 5.103
Authors: Ravi Tandon; Devi SenGupta; Lishomwa C Ndhlovu; Raphaella G S Vieira; R Brad Jones; Vanessa A York; Vinicius A Vieira; Elizabeth R Sharp; Andrew A Wiznia; Mario A Ostrowski; Michael G Rosenberg; Douglas F Nixon Journal: J Virol Date: 2011-08-31 Impact factor: 5.103
Authors: Jonah B Sacha; In-Jeong Kim; Lianchun Chen; Jakir H Ullah; David A Goodwin; Heather A Simmons; Daniel I Schenkman; Frederike von Pelchrzim; Robert J Gifford; Francesca A Nimityongskul; Laura P Newman; Samantha Wildeboer; Patrick B Lappin; Daisy Hammond; Philip Castrovinci; Shari M Piaskowski; Jason S Reed; Kerry A Beheler; Tharsika Tharmanathan; Ningli Zhang; Sophie Muscat-King; Melanie Rieger; Carla Fernandes; Klaus Rumpel; Joseph P Gardner; Douglas H Gebhard; Juliann Janies; Ahmed Shoieb; Brian G Pierce; Dusko Trajkovic; Eva Rakasz; Sing Rong; Michael McCluskie; Clare Christy; James R Merson; R Brad Jones; Douglas F Nixon; Mario A Ostrowski; Peter T Loudon; Ingrid M Pruimboom-Brees; Neil C Sheppard Journal: J Immunol Date: 2012-06-27 Impact factor: 5.422
Authors: Derek Dube; Rafael Contreras-Galindo; Shirley He; Steven R King; Marta J Gonzalez-Hernandez; Scott D Gitlin; Mark H Kaplan; David M Markovitz Journal: J Virol Date: 2014-06-11 Impact factor: 5.103
Authors: Rafael Contreras-Galindo; Mark H Kaplan; Philippe Leissner; Thibault Verjat; Ilaria Ferlenghi; Fabio Bagnoli; Fabiola Giusti; Michael H Dosik; Daniel F Hayes; Scott D Gitlin; David M Markovitz Journal: J Virol Date: 2008-07-16 Impact factor: 5.103
Authors: Daria Brinzevich; George R Young; Robert Sebra; Juan Ayllon; Susan M Maio; Gintaras Deikus; Benjamin K Chen; Ana Fernandez-Sesma; Viviana Simon; Lubbertus C F Mulder Journal: J Virol Date: 2014-03-19 Impact factor: 5.103
Authors: M Garcia-Montojo; S Fathi; G Norato; B R Smith; D B Rowe; M C Kiernan; S Vucic; S Mathers; R P A van Eijk; U Santamaria; M-L Rogers; A Malaspina; V Lombardi; P R Mehta; H-J Westeneng; L H van den Berg; A Al-Chalabi; J Gold; A Nath Journal: J Neurol Sci Date: 2021-02-23 Impact factor: 3.181